Citation: | ZHANG Wen-ting, GU Lin, KE Xi-quan, WANG Qi-zhi, WANG Qiang-wu, WANG Jian-chao, LI Da-peng. Expressions of TLR9 and STAT3 and their correlation with IL-10 in patients with ulcerative colitis[J]. Chinese Journal of General Practice, 2021, 19(6): 921-924. doi: 10.16766/j.cnki.issn.1674-4152.001950 |
[1] |
PINETON DE CHAMBRUN G, TASSY B, KOLLEN L, et al. The treatment of refractory ulcerative colitis[J]. Best Pract Res Clin Gastroenterol, 2018, 32-33: 49-57. doi: 10.1016/j.bpg.2018.05.009
|
[2] |
刘梦莹, 王启之. TLR9/NF-κBp65信号通路与溃疡性结肠炎[J]. 胃肠病学和肝病学杂志, 2015, 24(9): 1149-1151. https://www.cnki.com.cn/Article/CJFDTOTAL-WCBX201509033.htm
|
[3] |
ATREYA R, REINISCH W, PEYRIN-BIROULET L, et al. Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis[J]. Dig Liver Dis, 2018, 50(10): 1019-1029. doi: 10.1016/j.dld.2018.06.010
|
[4] |
BORZUTZKY A, RAUTER I, FRIED A, et al. Defective TLR9-driven STAT3 activation in B cells of patients with CVID[J]. Clin Immunol, 2018, 197: 40-44. doi: 10.1016/j.clim.2018.08.008
|
[5] |
吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201809007.htm
|
[6] |
RUBIN D T, ANANTHAKRISHNAN A N, SIEGEL C A, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413. doi: 10.14309/ajg.0000000000000152
|
[7] |
UNGARO R, MEHANDRU S, ALLEN P B, et al. Ulcerative colitis[J]. Lancet, 2017, 389(10080): 1756-1770. doi: 10.1016/S0140-6736(16)32126-2
|
[8] |
TAKEDA K, AKIRA S. Toll-Like Receptors[J]. Curr Protoc Immunol, 2015. DOI: 10.1002/0471142735.im1412s109.
|
[9] |
BING X, XUELEI L, WANWEI D, et al. EGCG maintains Th1/Th2 balance and mitigates ulcerative colitis induced by dextran sulfate sodium through TLR4/MyD88/NF-κB signaling pathway in rats[J]. Can J Gastroenterol, 2017, 2017: 3057268. http://europepmc.org/abstract/MED/29404307
|
[10] |
ANTHONEY N, FOLDI I, HIDALGO A. Toll and Toll-like receptor signalling in development[J]. Development, 2018, 145(9): dev156018. doi: 10.1242/dev.156018
|
[11] |
SCHMITT H, ULMSCHNEIDER J, BILLMEIER U, et al. The TLR9 agonist cobitolimod induces IL10-producing wound healing macrophages and regulatory T cells in ulcerative colitis[J]. J Crohns Colitis, 2020, 14(4): 508-524. doi: 10.1093/ecco-jcc/jjz170
|
[12] |
TIAN L, LI Y, ZHANG J, et al. IL-9 promotes the pathogenesis of ulcerative colitis through STAT3/SOCS3 signaling[J]. Biosci Rep, 2018, 38(6): BSR20181521. doi: 10.1042/BSR20181521
|
[13] |
CHEN Y Y, MA Z B, XU H Y, et al. IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis[J]. Int J Clin Exp Med, 2015, 8(8): 12009-12017. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612798/pdf/ijcem0008-12009.pdf
|
[14] |
JOFRA T, GALVANI G, COSORICH I, et al. Experimental colitis in IL-10-deficient mice ameliorates in the absence of PTPN22[J]. Clin Exp Immunol, 2019, 197(3): 263-275. doi: 10.1111/cei.13339
|
[15] |
BISWAS A, SHOUVAL D S, GRIFFITH A, et al. WASP-mediated regulation of anti-inflammatory macrophages is IL-10 dependent and is critical for intestinal homeostasis[J]. Nat Commun, 2018, 9(1): 1779. doi: 10.1038/s41467-018-03670-6
|